View Item 

Show simple item record

Licença compulsória do efavirenz no Brasil em 2007: contextualização

dc.contributor.authorRodrigues, William C. Ves_ES
dc.contributor.authorSoler, Orenzioes_ES
dc.date.accessioned2015
dc.date.available2015
dc.date.issued2009es_ES
dc.identifier.citationRodrigues, William C. V,Soler, Orenzio (2009) Licença compulsória do efavirenz no Brasil em 2007: contextualização. Rev Panam Salud Publica;26(6) 553-559,dez. 2009. Retrieved from http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892009001200012pt_BR
dc.identifier.urihttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892009001200012es_ES
dc.identifier.urihttps://iris.paho.org/handle/10665.2/9729
dc.relation.ispartofseriesRev Panam Salud Publica;26(6),dic. 2009es_ES
dc.subjectTerapia anti-retroviral de alta atividadees_ES
dc.subjectMedicamentoses_ES
dc.subjectPropriedade Intelectualpt_BR
dc.subjectPatenteses_ES
dc.subjectBrasilpt_BR
dc.subjectAntiretroviral Therapy, Highly Activees_ES
dc.subjectDrugses_ES
dc.subjectIntellectual Propertyes_ES
dc.subjectPatentses_ES
dc.subjectBrazilen_US
dc.subjectFármacos Anti-HIVes_ES
dc.subjectBenzoxazinases_ES
dc.subjectPatentes como Assuntoes_ES
dc.subjectBrasilpt_BR
dc.titleLicença compulsória do efavirenz no Brasil em 2007: contextualizaçãopt_BR
dc.typeJournal articlesen_US
dc.rights.holderPan American Health Organizationen_US
dc.description.notesThe present article aims at contextualizing the first Brazilian experience with compulsory licensing, which functions as a defense mechanism to prevent excessive pricing by holders of patents. According to this mechanism, a government can authorize a third party to explore the patented object (in this case a drug) without previous consent from the patent holder. On May 4, 2007, Brazil officially issued compulsory licensing of the antiretroviral drug efavirenz for public, non-commercial use. Initially, generic versions of the drug were purchased from laboratories in India. The next step was the manufacture of efavirenz by Farmanguinhos, official pharmaceutical laboratory (Fundação Osvaldo Cruz). It is concluded that the decision made by the Brazilian government to issue compulsory licensing of efavirenz nwas correct, taking into account the projected savings of US$ 236.8 until 2012 and the guarantee of availability of efavirenz, the most usual free antiretroviral treatment provided in Brazil.(AU)pt_BR


Files in this item

Thumbnail
Name:
12.pdf
Size:
69.81Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record